Avertix Medical

Avertix Medical

医疗设备制造业

First and only FDA-Approved Implantable Cardiac Surveillance System | A New Day Dawns for Heart Attack Survivors and ACD

关于我们

Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we’re dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix’s Guardian? is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

网站
www.avertix.com
所属行业
医疗设备制造业
规模
51-200 人
类型
私人持股
创立
2001

地点

Avertix Medical员工

动态

相似主页

查看职位

融资

Avertix Medical 共 1 轮

上一轮

可转债

US$13,480,307.00

Crunchbase 上查看更多信息